Concepedia

Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Julien Bollard, Christophe Couderc, Martine Blanc, Gilles Poncet, Florian Lépinasse, Valérie Hervieu, Géraldine Gouysse, Carole Ferraro‐Peyret, Noura Benslama, Thomas Walter,

Neuroendocrinology · 2013 · 33 citations · 20 references

DOIFull text

Open access

Abstract

Our experimental data suggest that mTOR inhibition could be considered a therapeutic option for high-grade gastroenteropancreatic neuroendocrine tumors.

References

20

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +5

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations

<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

Yuchen Jiao, Chanjuan Shi, Barish H. Edil et al. · Science · 2011 · 1.7K citations

, , +28

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1K citations

, , +8